blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2797617

EP2797617 - ANTI-TUMOR ADJUVANT THERAPY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.11.2020
Database last updated on 10.07.2024
FormerThe patent has been granted
Status updated on  20.12.2019
FormerGrant of patent is intended
Status updated on  25.08.2019
FormerExamination is in progress
Status updated on  10.02.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Sorbonne Université
21 rue de l'École de Médecine
75006 Paris / FR
For all designated states
Institut Curie
26, rue d'Ulm
75248 Paris Cedex 05 / FR
[2018/27]
Former [2014/45]For all designated states
Université Pierre et Marie Curie (Paris 6)
4, Place Jussieu
75005 Paris / FR
For all designated states
Institut Curie
26, rue d'Ulm
75248 Paris Cedex 05 / FR
Inventor(s)01 / REBOLLO GARCIA, Angelita
6 rue Gramme
F-75015 Paris / FR
02 / NEMATI, Fariba
5 rue Jean Cottin
F-75018 Paris / FR
03 / DECAUDIN, Didier
117 rue d'Estiennes d'Orves
F-91370 Verrieres Le Buisson / FR
 [2014/45]
Representative(s)Chajmowicz, Marion, et al
Becker & Associés
25, Rue Louis Le Grand
75002 Paris / FR
[N/P]
Former [2014/45]Chajmowicz, Marion, et al
Becker & Associés
25, rue Louis Le Grand
75002 Paris / FR
Application number, filing date12816305.227.12.2012
[2020/04]
WO2012EP76970
Priority number, dateEP2011030678527.12.2011         Original published format: EP 11306785
[2014/45]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013098339
Date:04.07.2013
Language:EN
[2013/27]
Type: A1 Application with search report 
No.:EP2797617
Date:05.11.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 04.07.2013 takes the place of the publication of the European patent application.
[2014/45]
Type: B1 Patent specification 
No.:EP2797617
Date:22.01.2020
Language:EN
[2020/04]
Search report(s)International search report - published on:EP04.07.2013
ClassificationIPC:A61K38/17, C07K14/47, C07K19/00, A61P35/00, A61K31/337, A61K31/513, A61K31/664, A61K31/704, A61K31/24, C12N9/64, A61K38/10, A61K33/24
[2019/35]
CPC:
A61K38/10 (EP,US); A61K31/337 (EP,US); A61K31/513 (EP,US);
A61K31/664 (EP,US); A61K31/704 (EP,US); A61K33/243 (EP,US);
A61P35/00 (EP); A61P35/02 (EP); A61P43/00 (EP);
C07K14/4747 (EP,US); C07K7/08 (US); C12N9/6475 (EP,US);
A61K38/00 (EP,US); C07K2319/10 (EP,US) (-)
Former IPC [2014/45]A61K38/17, C07K14/47, C07K19/00, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/45]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:THERAPIE MIT ANTITUMORHILFSSTOFF[2019/35]
English:ANTI-TUMOR ADJUVANT THERAPY[2014/45]
French:THÉRAPIE D'ADJUVANT ANTI-TUMEUR[2019/35]
Former [2014/45]THERAPIE MIT EINEM ANTITUMORHILFSSTOFF
Former [2014/45]THÉRAPIE ADJUVANTE ANTITUMORALE
Entry into regional phase22.07.2014National basic fee paid 
22.07.2014Designation fee(s) paid 
22.07.2014Examination fee paid 
Examination procedure22.07.2014Amendment by applicant (claims and/or description)
22.07.2014Examination requested  [2014/45]
10.02.2017Despatch of a communication from the examining division (Time limit: M06)
14.08.2017Reply to a communication from the examining division
08.02.2019Despatch of a communication from the examining division (Time limit: M04)
06.06.2019Reply to a communication from the examining division
26.08.2019Communication of intention to grant the patent
16.12.2019Fee for grant paid
16.12.2019Fee for publishing/printing paid
16.12.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  10.02.2017
Opposition(s)23.10.2020No opposition filed within time limit [2020/53]
Fees paidRenewal fee
30.12.2014Renewal fee patent year 03
14.12.2015Renewal fee patent year 04
06.12.2016Renewal fee patent year 05
18.12.2017Renewal fee patent year 06
10.12.2018Renewal fee patent year 07
10.12.2019Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.12.2012
AL22.01.2020
AT22.01.2020
CY22.01.2020
CZ22.01.2020
DK22.01.2020
EE22.01.2020
ES22.01.2020
FI22.01.2020
HR22.01.2020
IT22.01.2020
LT22.01.2020
LV22.01.2020
MC22.01.2020
MK22.01.2020
MT22.01.2020
NL22.01.2020
PL22.01.2020
RO22.01.2020
RS22.01.2020
SE22.01.2020
SI22.01.2020
SK22.01.2020
SM22.01.2020
TR22.01.2020
BG22.04.2020
NO22.04.2020
GR23.04.2020
IS22.05.2020
PT14.06.2020
[2022/31]
Former [2022/30]HU27.12.2012
AL22.01.2020
AT22.01.2020
CY22.01.2020
CZ22.01.2020
DK22.01.2020
EE22.01.2020
ES22.01.2020
FI22.01.2020
HR22.01.2020
IT22.01.2020
LT22.01.2020
LV22.01.2020
MC22.01.2020
MT22.01.2020
NL22.01.2020
PL22.01.2020
RO22.01.2020
RS22.01.2020
SE22.01.2020
SI22.01.2020
SK22.01.2020
SM22.01.2020
TR22.01.2020
BG22.04.2020
NO22.04.2020
GR23.04.2020
IS22.05.2020
PT14.06.2020
Former [2022/27]HU27.12.2012
AT22.01.2020
CY22.01.2020
CZ22.01.2020
DK22.01.2020
EE22.01.2020
ES22.01.2020
FI22.01.2020
HR22.01.2020
IT22.01.2020
LT22.01.2020
LV22.01.2020
MC22.01.2020
MT22.01.2020
NL22.01.2020
PL22.01.2020
RO22.01.2020
RS22.01.2020
SE22.01.2020
SI22.01.2020
SK22.01.2020
SM22.01.2020
TR22.01.2020
BG22.04.2020
NO22.04.2020
GR23.04.2020
IS22.05.2020
PT14.06.2020
Former [2022/26]AT22.01.2020
CZ22.01.2020
DK22.01.2020
EE22.01.2020
ES22.01.2020
FI22.01.2020
HR22.01.2020
IT22.01.2020
LT22.01.2020
LV22.01.2020
MC22.01.2020
NL22.01.2020
PL22.01.2020
RO22.01.2020
RS22.01.2020
SE22.01.2020
SI22.01.2020
SK22.01.2020
SM22.01.2020
TR22.01.2020
BG22.04.2020
NO22.04.2020
GR23.04.2020
IS22.05.2020
PT14.06.2020
Former [2021/40]AT22.01.2020
CZ22.01.2020
DK22.01.2020
EE22.01.2020
ES22.01.2020
FI22.01.2020
HR22.01.2020
IT22.01.2020
LT22.01.2020
LV22.01.2020
MC22.01.2020
NL22.01.2020
PL22.01.2020
RO22.01.2020
RS22.01.2020
SE22.01.2020
SI22.01.2020
SK22.01.2020
SM22.01.2020
BG22.04.2020
NO22.04.2020
GR23.04.2020
IS22.05.2020
PT14.06.2020
Former [2021/10]AT22.01.2020
CZ22.01.2020
DK22.01.2020
EE22.01.2020
ES22.01.2020
FI22.01.2020
HR22.01.2020
IT22.01.2020
LT22.01.2020
LV22.01.2020
NL22.01.2020
PL22.01.2020
RO22.01.2020
RS22.01.2020
SE22.01.2020
SI22.01.2020
SK22.01.2020
SM22.01.2020
BG22.04.2020
NO22.04.2020
GR23.04.2020
IS22.05.2020
PT14.06.2020
Former [2020/50]CZ22.01.2020
DK22.01.2020
EE22.01.2020
ES22.01.2020
FI22.01.2020
HR22.01.2020
LT22.01.2020
LV22.01.2020
NL22.01.2020
RO22.01.2020
RS22.01.2020
SE22.01.2020
SK22.01.2020
SM22.01.2020
BG22.04.2020
NO22.04.2020
GR23.04.2020
IS22.05.2020
PT14.06.2020
Former [2020/49]CZ22.01.2020
DK22.01.2020
ES22.01.2020
FI22.01.2020
HR22.01.2020
LT22.01.2020
LV22.01.2020
NL22.01.2020
RO22.01.2020
RS22.01.2020
SE22.01.2020
SK22.01.2020
SM22.01.2020
BG22.04.2020
NO22.04.2020
GR23.04.2020
IS22.05.2020
PT14.06.2020
Former [2020/48]DK22.01.2020
ES22.01.2020
FI22.01.2020
HR22.01.2020
LT22.01.2020
LV22.01.2020
NL22.01.2020
RO22.01.2020
RS22.01.2020
SE22.01.2020
SM22.01.2020
BG22.04.2020
NO22.04.2020
GR23.04.2020
IS22.05.2020
PT14.06.2020
Former [2020/47]DK22.01.2020
ES22.01.2020
FI22.01.2020
HR22.01.2020
LT22.01.2020
LV22.01.2020
NL22.01.2020
RS22.01.2020
SE22.01.2020
BG22.04.2020
NO22.04.2020
GR23.04.2020
IS22.05.2020
PT14.06.2020
Former [2020/40]FI22.01.2020
HR22.01.2020
LV22.01.2020
NL22.01.2020
RS22.01.2020
SE22.01.2020
BG22.04.2020
NO22.04.2020
GR23.04.2020
IS22.05.2020
PT14.06.2020
Former [2020/39]FI22.01.2020
HR22.01.2020
LV22.01.2020
NL22.01.2020
RS22.01.2020
SE22.01.2020
BG22.04.2020
NO22.04.2020
GR23.04.2020
PT14.06.2020
Former [2020/38]FI22.01.2020
HR22.01.2020
LV22.01.2020
NL22.01.2020
RS22.01.2020
SE22.01.2020
NO22.04.2020
GR23.04.2020
PT14.06.2020
Former [2020/37]FI22.01.2020
HR22.01.2020
LV22.01.2020
NL22.01.2020
RS22.01.2020
SE22.01.2020
NO22.04.2020
PT14.06.2020
Former [2020/36]FI22.01.2020
NL22.01.2020
RS22.01.2020
NO22.04.2020
PT14.06.2020
Former [2020/35]FI22.01.2020
NL22.01.2020
NO22.04.2020
Former [2020/33]NL22.01.2020
Cited inInternational search[Y]WO2004011595  (PASTEUR INSTITUT [FR], et al) [Y] 1-18 * the whole document * * example -; claim - *;
 [YD]WO2010112471  (UNIV PARIS CURIE [FR], et al) [YD] 1-18 * the whole document * * example -; claim -; sequences 2,3 *;
 [XP]WO2012042038  (INST NAT SANTE RECH MED [FR], et al) [XP] 1-18 * the whole document * * pages 20,21; example -; claim - *;
 [Y]  - F. NEMATI ET AL, "Abstract A205: Targeting caspase-9/PP2A interaction as a new antitumor strategy.", MOLECULAR CANCER THERAPEUTICS, (20111112), vol. 10, no. Supplement 1, doi:10.1158/1535-7163.TARG-11-A205, ISSN 1535-7163, pages A205 - A205, XP055056257 [Y] 1-18 * abstract *

DOI:   http://dx.doi.org/10.1158/1535-7163.TARG-11-A205
 [A]  - GUERGNON J ET AL, "Use of penetrating peptides interacting withPP1/PP2A proteins as a general approach for a drug phosphatase technology", MOLECULAR PHARMACOLOGY, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, (20060401), vol. 69, no. 4, doi:10.1124/MOL.105.019364, ISSN 0026-895X, pages 1115 - 1124, XP002439305 [A] 1-18

DOI:   http://dx.doi.org/10.1124/mol.105.019364
 [A]  - JULIEN GUERGNON ET AL, "A PKA survival pathway inhibited by DPT-PKI, a new specific cell permeable PKA inhibitor, is induced by T. annulata in parasitized B-lymphocytes", APOPTOSIS ; AN INTERNATIONAL JOURNAL ON PROGRAMMED CELL DEATH, KLUWER ACADEMIC PUBLISHERS, BO, (20060605), vol. 11, no. 8, doi:10.1007/S10495-006-7702-6, ISSN 1573-675X, pages 1263 - 1273, XP019390818 [A] 1-18

DOI:   http://dx.doi.org/10.1007/s10495-006-7702-6
by applicantUS5468223
 US2007184015
 WO2010112471
    - NEMATI ET AL., ANTI CANCER DRUGS, (2009), vol. 20, pages 932 - 940
    - DENG X; GAO F; W. STRATFORD MAY, "Dephosphorylation and up-regulation of Bcl2-p53 binding Protein phosphatase 2A inactivates Bcl-2's antiapoptotic function by dephosphorylation and up-regulation of Bcl2-p53 binding", BLOOD, (20090108), vol. 113, no. 2, pages 422 - 8
    - LEHNINGER, Biochemistry, WORTH PUBLISHERS, INC., (1975), pages 71 - 77
    - MARANGONI ET AL., CLINICAL CANCER RESEARCH, (2007), vol. 13, pages 3989 - 3998
    - PRICKETT TD; BRAUTIGAN D, "Ovelapping binding sites in Protein Phosphatase 2A for association with regulatory 1 and a4 (mTap42) subunits", J.BIOL.CHEM., (2004), vol. 279, pages 38912 - 38920
    - WALENSKY ET AL., SCIENCE, (2004), vol. 305, pages 1466 - 1470
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.